Basic Information
Trixeo Aerosphere
Regulatory Information
EMEA/H/C/004983
December 9, 2020
October 15, 2020
6
December 13, 2024
Company Information
Active Substances Detail
formoterol fumarate dihydrateGlycopyrronium bromideBudesonide
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Trixeo Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.
Overview Summary
Trixeo Aerosphere is a medicine used to treat patients with moderate to severe chronic obstructive pulmonary disease (COPD), a long-term disease in which the airways and air sacs in the lungs become damaged or blocked, leading to difficulty breathing. Trixeo Aerosphere is used for maintenance (regular) treatment in adults whose disease is not controlled well enough with a combination of inhaled medicines consisting of a long-acting beta-2 agonist plus either a corticosteroid or a long-acting muscarinic antagonist. Trixeo Aerosphere contains the active substances formoterol, glycopyrronium bromide and budesonide.